During the past decade, Krankenhaus Muenchen Schwabing conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Krankenhaus Muenchen Schwabing" #1 sponsor was "German CLL Study Group" with 8 trials, followed by "University of Ulm" with 4 trials sponsored, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 3 trials sponsored, "Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany" with 3 trials sponsored and "Biotronik AG" with 3 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Krankenhaus Muenchen Schwabing" #1 collaborator was "AbbVie" with 2 trials as a collaborator, "Cancer Trials Ireland" with 2 trials as a collaborator, "German CLL Study Group" with 2 trials as a collaborator, "Janssen-Cilag Ltd." with 2 trials as a collaborator and "Nordic CLL Study Group (NCLLSG)" with 2 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 40 trials.

According to Clinical.Site data, the most researched conditions in "Krankenhaus Muenchen Schwabing" are "Chronic Lymphocytic Leukemia" (8 trials), "Lymphoma" (6 trials), "Leukemia" (3 trials), "Acute Myeloid Leukemia" (2 trials) and "Chronic Lymphoid Leukemia" (2 trials). Many other conditions were trialed in "Krankenhaus Muenchen Schwabing" in a lesser frequency.

Most popular intervention types in "Krankenhaus Muenchen Schwabing" are "Drug" (23 trials), "Biological" (14 trials), "Radiation" (10 trials), "Procedure" (7 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (9 trials), "radiation therapy" (9 trials), "filgrastim" (7 trials), "vincristine sulfate" (7 trials) and "Obinutuzumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Krankenhaus Muenchen Schwabing" are 30 trials for "All" genders.

Currently, there are NaN active trials in "Krankenhaus Muenchen Schwabing". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Krankenhaus Muenchen Schwabing, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Krankenhaus Muenchen Schwabing, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".